Main description:

Written by the pioneers of Viagra, the first blockbuster PDE inhibitor drug. Beginning with a review of the first wave of phosphodiesterase (PDE) inhibitors, this book focuses on new and emerging PDE targets and their inhibitors. Drug development options are discussed according to the therapeutic field, covering neurological/psychiatric, cardiovascular/metabolic, pain, and allergy/respiratory diseases. The final section discusses the structural biology of PDE, as well as the emerging chemotherapeutic applications of PDE inhibitors against malaria and other tropical diseases.

Contents:

INTRODUCTION The PDE gene family in drug discovery The origins of drugability: The discovery of PDE-5 inhibitors for erectile dysfunction Recent advances and new therapeutic utilities for PDE-5 inhibitors PSYCHIATRIC AND NEUROLOGICAL DISORDERS General overview PDE-10 inhibitors for schizophrenia PDE-9 inhibitors for cognitive deficits diseases PDE-4 inhibitors for CNS indications PDE-2 inhibitors for CNS indications CARDIOVASCULAR AND METABOLIC DISEASES General overview PDE-8 inhibitors for the treatment of diabetes PDE-7/8 inhibitors PAIN THERAPY PDE-7 inhibitors for the treatment of pain ALLERGY AND RESPIRATORY DISEASES PDE-4 inhibitors as treatments for allergy and respiratory disease Selective PDE inhibitors for COPD NON-MAMMALIAN TARGETS Malaria PDEs Trypanosome cruzei PDEs STRUCTRUAL BIOLOGY OF PHOSPHODIESTERASES Impact of PDE structural biology on drug discovery Structural biology of PDE-1 and PDE-4 inhibitors